Source: Annual Congress 2002 - Asthma - Therapy and management -1
Disease area: Airway diseases

Abstract

To evaluate the total cost of reliever therapy, formoterol Turbuhaler® (Oxis®) 4.5 μg (F) and salbutamol 200 μg (S) via a pMDI or dry powder inhaler (DPI) stratified by maintenance treatment according to GINA guidelines. 18,124 patients aged 4–91 y, with different severities of asthma and receiving a variety of maintenance medication, entered this, 6-month, open, parallel-group trial. Cost (€) of asthma drugs and health care resource use due to asthma were collected using year 2000 prices in Sweden. At study entry, asthma medication level was classified as: Intermittent, no maintenance; Mild, ICS <500 μg/day; Moderate, ICS >500 μg/day or 500–800 μg/day + long-acting β₂-agonist (LABA); Severe, ICS>800 μg + LABA. Reliever costs were presented for salbutamol DPI (Ventolin®) and pMDI (generic). Health care resource use was lower on F compared with S. Total daily cost according to reliever and medication level is presented in Euros. No significant differences were detected.

	F	S DPI	S pMDI
Intermittent	1.33	1.11	0.99
Mild	2.32	2.27	2.14
Moderate	3.65	3.35	3.21
Severe	6.67	6.99	6.77
All	3.26	3.18	3.04

Across all patient sub-groups, reliever therapy with Oxis® was not associated with a significant increase in total daily costs in Sweden compared with salbutamol.

Rating:

Share or cite this content

Citations should be made in the following way:
Total costs according to reliever use of formoterol turbuhaler in asthma: results from the RELIEF worldwide randomized effectiveness study, stratified by maintenance medication levels. Eur Respir J 2002; 20: Suppl. 38, 390

Member's Comments

No comment yet.

Related content which might interest you: Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002 Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 Safety of formoterol turbuhaler used as reliever in asthma: relationship with age and baseline treatment including regular long-acting β2-agonists (the RELIEF study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002 Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study Source: Eur Respir J 2006; 28: Suppl. 50, 613s Year: 2006 Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: outcomes from the RELIEF study in patients across different severities and age groups Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002 Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002 Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial Source: Eur Respir J 2003; 22: 787-794 Year: 2003 Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Safety of formoterol turbuhaler when used as a reliever therapy in asthma (the RELIEF study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002 Healthcare resource use following addition of montelukast to budesonide compared to doubling the dose of budesonide in patients with inadequately controlled asthma (COMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004 Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004 Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double-blind study Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma Source: ERJ Open Res, 7 (4) 00271-2021; 10.1183/23120541.00271-2021 Year: 2021 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality: INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations) study Source: Eur Respir J 2007; 30: Suppl. 51, 34s Year: 2007